Documentation Expectations and Pre-Transplant Disease/MRD Documentation

Documentation must demonstrate disease status, prior therapies, response to therapy, and pre-transplant risk assessment. Include explicit documentation of remission status (CR/CRi), molecular minimal residual disease (MRD) testing results when applicable (for example, PML-RARα RT-PCR for APL, BCR-ABL MRD for Ph+ ALL), and response to CAR-T or TKI therapy if relevant.

• Pre-transplant disease documentation: date and type of last disease assessment, imaging/labs, bone marrow biopsy results
• MRD documentation: method (PCR/flow), quantitative result and date; document MRD-negative vs MRD-positive status
• Document CAR-T response: CR vs CR with MRD-negativity and duration of response prior to considering consolidative HSCT
• Document TKI response: type of TKI, duration of therapy, molecular response within 3 months when relevant (e.g., Ph+ ALL)

Transplant-Related Mortality and Comorbidity Risk

Coverage decisions for allogeneic HCT are influenced by transplant-related mortality (TRM) risk and comorbidities. High expected TRM or significant comorbidity burden may lead to denial or non-coverage of allogeneic HCT. Providers should include HSCT-specific comorbidity index (HCT-CI), performance status, and organ function testing in submissions.

• TRM affects coverage decisions — include documented estimates or clinical justification if TRM is elevated
• Comorbidity-related denial risk: submit HCT-specific comorbidity index and explain how comorbidities are being managed or mitigated
• Performance status and organ function: ECOG/KPS, cardiac, pulmonary, hepatic, renal evaluations

Therapy Sequencing and Step-Therapy Considerations

Therapy sequencing and step-therapy considerations should be documented. For certain diseases (e.g., Ph+ ALL), documentation of an adequate trial and response to tyrosine kinase inhibitor (TKI) therapy is expected prior to proceeding to HSCT when guideline-concordant. Consideration of non-transplant consolidation (for example, further systemic therapy or observation) should be noted when applicable.

• Step therapy: document TKI use and molecular response (CMR) within recommended timeframes (often ~3 months) prior to HSCT consideration
• Consider non-transplant consolidation before HSCT when guidelines support observation or further consolidation (e.g., certain APL or RS scenarios)
• Document prior lines of therapy, dates, responses, and rationale for proceeding to transplant vs continued non-transplant management

Authorization Omissions and Common Denial Triggers

Operational expectations and denial triggers: when prior authorization is not obtained or required elements are missing, coverage may be delayed or denied. This section summarizes provider actions that commonly affect eligibility and adjudication.

• No explicit authorization: if prior authorization is not obtained where required, claims may be denied or returned for retro-review
• Denial triggers for allogeneic HCT: inadequate documentation of chemo-sensitivity/response, unacceptable TRM/comorbidity profile, lack of suitable donor documentation, or missing MRD/disease assessments
• No explicit additional denial triggers are specified within this fragment beyond documentation and medical-necessity considerations

Transplant Center and Donor Evaluation Requirements

Referral to and selection by a transplant center is required to confirm eligibility. The transplanting institution must document its selection criteria and confirm donor compatibility testing (including HLA typing and crossmatch) and infectious disease screening prior to transplant.

• Center requirements: transplant center selection criteria and attestation of eligibility must be included in the record
• Donor evaluation: include HLA typing, compatibility testing results, donor infectious disease screening, and donor source/type
• Prior authorization should reflect whether transplant center acceptance has been obtained

Policy History, Evidence, and Citation Expectations

Policy history and supporting references should be included in the medical record submission when relevant to clinical rationale. Providers should cite guideline sources or recent evidence if relying on non-standard sequencing (for example, use of next-generation TKIs in lieu of HSCT in MRD-negative Ph+ ALL).

• Include relevant guideline citations (e.g., NCCN, UpToDate) or recent studies supporting the chosen management pathway
• Document date of last policy review or institutional guideline when used to justify deviation from typical care pathways

Prior authorization required for transplant procedure codes

Obtain prior authorization for listed transplant‑related CPT/HCPCS codes (for example 38205, 38230, 38240, 86813, 86817, 86821, S2150); coverage is contingent on meeting the policy's selection/medical‑necessity criteria.

• Prior authorization required for codes: 38205, 38206‑38215, 38230, 38232, 38240, 38241, 38242, 86813, 86817, 86821, 0251U, S2150 (as listed)
• Provide documentation that selection criteria/medical necessity are met when requesting authorization

Donor‑ and risk‑stratified authorization: align requests with cytogenetic risk

Authorization decisions should reflect donor‑ and cytogenetic risk stratification (for example, allo‑HSCT is recommended for poor‑risk and some intermediate‑risk AML in CR1); ensure documentation aligns with risk‑stratified indications.

• Document cytogenetic risk category and rationale for allo‑HSCT in CR1 when applicable
• Include donor availability and donor type considerations in authorization materials

Transplant center evaluation required to confirm eligibility

Refer members to and obtain evaluation from a transplant center to confirm eligibility; the center evaluation should document organ function, performance status, and donor availability to support authorization.

• Transplant center must confirm fitness, organ function, and donor suitability
• Include transplant center evaluation notes with authorization request

Prior authorization: consolidative HSCT after CD19 CAR‑T — document CR/MRD

When requesting authorization for consolidative HSCT after CD19 CAR‑T, provide documentation of CR or MRD status because meta‑analysis demonstrated improved overall survival and reduced relapse with consolidative HSCT.

• Document CR and MRD status following CAR‑T in the prior authorization submission
• Cite evidence of benefit (meta‑analysis) when applicable to support medical necessity

Prior authorization: no additional steps specified here

This section of the policy does not list additional specific prior authorization steps beyond code‑level authorization and meeting selection criteria; use the listed codes and selection criteria when preparing requests.

• Follow code list and medical necessity criteria; no other concrete prior authorization steps specified in this fragment

Therapy sequencing: document prior therapies and transplant history

Document prior lines of therapy and prior autologous transplant status when applicable; coverage considerations reference sequencing (e.g., transplant for relapsed/refractory disease after conventional therapy).

• List prior systemic therapies, response, and dates
• Document prior autologous HSCT if applicable

Consider non‑transplant consolidation before HSCT in some AML CR1 patients

Consider and document use of non‑transplant consolidation (e.g., consolidation chemotherapy) in AML CR1 patients when appropriate; evidence supports reserving transplant based on donor availability and cytogenetic risk.

• If non‑transplant consolidation chosen, describe rationale and cytogenetic risk to justify alternative to HSCT

Pre‑HCT therapy: document intensified chemotherapy and response in older ALL patients

For older ALL patients, document prior intensified chemotherapy regimens and response; authorization should include this information when allo‑HCT is being considered after intensified therapy.

• Include treatment regimens, dates, and response in authorization documentation

Step therapy: document TKI response and MRD before HSCT for Ph+ ALL

For Ph+ ALL, document response to tyrosine kinase inhibitor (TKI) therapy and MRD status before HSCT authorization, since next‑generation TKIs ± chemotherapy may achieve comparable survival to allo‑HSCT in MRD‑negative patients.

• Provide molecular response (CMR/MRD) after TKI therapy and duration of response
• If MRD‑negative after next‑generation TKI, include rationale if HSCT is still being requested

Clinical sequencing references: no explicit payer step‑therapy rules

Clinical publications in the references discuss sequencing (consolidation, transplant after remission) but the policy does not impose specific payer step‑therapy rules beyond documenting prior therapy and response.

• Clinical citation context provided but no payer step‑therapy mandates stated

Documentation: confirm member meets transplanting institution's selection criteria

Provide documentation that the member meets the transplanting institution's selection criteria (or applicable Aetna indications) including remission status, prior treatment response, donor availability, and fitness to tolerate the procedure.

• Include confirmation that institutional selection criteria are met
• Attach transplant center evaluation or institutional eligibility statement

Pre‑transplant documentation: molecular MRD and prior CR duration (APL example)

Include molecular MRD results (for example PML‑RARα in APL) and prior complete remission duration in pre‑transplant documentation because these elements affect auto‑ versus allo‑HSCT decisions.

• Provide RT‑PCR or other molecular assay results (e.g., PML‑RARα) and date
• Report duration of prior CR(s)

Pre‑transplant documentation: comorbidity index, performance status, organ function

Document HSCT‑specific comorbidity index, performance status, organ function tests, and demonstration of chemo‑sensitive disease where applicable to support candidacy and authorization.

• Record HSCT‑specific comorbidity index score and interpretation
• Provide organ function labs and imaging supporting fitness for transplant

Document CAR‑T response (CR/MRD) for consolidative HSCT requests

When consolidative HSCT is being considered after CD19 CAR‑T, document prior CAR‑T response status (CR or MRD‑negative CR) because outcomes differ by response and this information supports authorization.

• Provide CR status and MRD results following CAR‑T in the authorization packet

Denial risk: missing institution selection criteria for ALL allogeneic HCT

Allogeneic HCT for ALL is medically necessary only when members meet the transplanting institution's selection criteria (or, absent institutional criteria, not in refractory relapse); absence of documentation meeting these criteria may lead to denial.

• Refractory relapse is defined as relapse unresponsive to ≥3 months of adequate chemotherapy — absence of evidence of meeting selection criteria risks non‑approval

Denial risk: high TRM may negate benefit in older/high‑risk patients

Be aware that high transplant‑related mortality (TRM) in older or high‑risk patients can abrogate survival benefit; lack of documentation addressing TRM risk and expected benefit may influence coverage decisions.

• Provide risk/benefit discussion and justification when TRM risk is elevated (e.g., older/high‑risk patients)

Denial risk: high comorbidity increases risk of poor outcomes and possible non‑approval

Document comorbidity burden using an HSCT‑specific comorbidity index because higher comorbidity scores are associated with worse overall survival after HSCT; absence of fitness documentation may increase risk of denial.

• Include HSCT comorbidity index score and explanation in authorization materials

Authorization context: background evidence only, no explicit authorization steps

This background evidence section does not specify further authorization requirements; it provides contextual evidence and guideline citations only.

• Use cited evidence to inform clinical justification but follow code‑level and selection‑criteria requirements for authorization

Administrative note: no denial triggers in policy history section

This administrative section contains policy history and notices and does not list denial triggers or provider action requirements.

• Policy last review date and effective date are administrative details